Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
5
×
boston top stories
life sciences
national blog main
national top stories
roche
5
×
deals
clinical trials
fda
san francisco blog main
san francisco top stories
avapritinib
blueprint medicines
eli lilly
europe blog main
europe top stories
genentech
investing
medullary thyroid cancer
non-small cell lung cancer
novartis
pralsetinib
selpercatinib
thyroid cancer
alexion pharmaceuticals
alnylam pharmaceuticals
biofourmis
biopharma
biovotion
boehringer ingelheim
cancer
cancer drugs
capmatinib
chugai pharmaceutical
cstone pharmaceuticals
dicerna pharamceuticals
duchenne
edbi
What
approval
drug
fda
medicines
roche
blueprint
cancer
gene
ret
team
therapeutics
therapy
address
analytics
approves
betting
billion
biofourmis
biopharma
candidate
carries
caught
causing
certain
currently
data
deal
designed
devices
dicerna
digital
disease
duchenne
employs
eye
genetic
globally
hauls
help
hepatitis
Language
unset
5
×
Current search:
roche
×
unset
×
" boston blog main "
×
boston
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug